Related Experiment Video
Updated: Feb 2, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Association between matrix-metalloproteinase polymorphisms and prostate cancer risk: a meta-analysis and systematic
1Department of Clinical Laboratory, Changzhou Second Hospital affiliated to Nanjing Medical University, Changzhou, Jiangsu Province, China.
Background:
Data from published articles on the relationship between MMP polymorphisms and prostate cancer risk are conflicted and inconclusive, so a meta-analysis and systematic review were performed to assess the relationship.
Methods:
Relevant research articles were identified from databases using a search strategy. Studies with the same MMP polymorphisms that could be quantitatively synthesized were included in the meta-analysis. Five comparison models (homozygote, heterozygote, dominant, recessive, and additive) were applied, and a subgroup analysis by case-group sample type was performed. Studies with different polymorphisms that could not be quantitatively synthesized were included in the systematic review.
Results:
Eleven articles encompassing 22 studies involving 12 MMP polymorphisms were included in this paper. Among the studies included, 13 studies involving MMP1 rs1799750, MMP2 rs243865, and MMP7 rs11568818 were quantitatively synthesized for meta-analysis, and the other nine studies involving nine polymorphisms (MMP2 rs2285053, MMP2 rs1477017, MMP2 rs17301608, MMP2 rs11639960, MMP3 11715A/6A, MMP3 1161A/G, MMP3 5356A/G, MMP9 rs17576, and MMP13 rs2252070) were included in the systematic review. Meta-analysis showed no associations between MMP1 rs1799750, MMP2 rs243865, or MMP7 rs11568818 and prostate cancer risk overall. Subgroup analysis by case-group sample type confirmed that no associations existed. The systematic review suggested that MMP3 11715A/6A and MMP9 rs17576 were associated with prostate cancer risk.
Conclusion:
MMP polymorphisms are not associated with prostate cancer risk, except for MMP3 11715A/6A and MMP9 rs17576. However, it is necessary to conduct larger-scale, high-quality studies in future.
Insights
Matrix metalloproteinase (MMP) gene polymorphisms show no overall link to prostate cancer risk. However, specific MMP3 and MMP9 variants may be associated with increased risk, warranting further investigation.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- Conflicting data exists on the association between matrix metalloproteinase (MMP) gene polymorphisms and prostate cancer risk.
- A comprehensive meta-analysis and systematic review were conducted to clarify these relationships.
Purpose of the Study:
- To systematically evaluate the association between various MMP gene polymorphisms and prostate cancer risk.
- To synthesize existing evidence using meta-analysis and systematic review methodologies.
Main Methods:
- A systematic literature search was performed across multiple databases.
- Meta-analysis included studies with quantifiable MMP polymorphisms using five genetic models.
- Systematic review covered studies with non-quantifiable polymorphisms.
Main Results:
- Meta-analysis of MMP1 rs1799750, MMP2 rs243865, and MMP7 rs11568818 revealed no association with prostate cancer risk.
- Subgroup analysis by sample type confirmed the lack of association for these polymorphisms.
- Systematic review indicated potential associations for MMP3 11715A/6A and MMP9 rs17576 with prostate cancer risk.
Conclusions:
- Matrix metalloproteinase (MMP) polymorphisms are generally not associated with prostate cancer risk.
- Specific variants, MMP3 11715A/6A and MMP9 rs17576, may be linked to prostate cancer.
- Larger, high-quality studies are recommended for future research.
Related Concept Videos
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Relative Risk
Random and Systematic Errors
Cancer Survival Analysis
Directing Effect of Substituents: meta-Directing Groups

